Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration

Journal of Drug Targeting

Volumn 16, Issue 5, 2008, Pages 357-365

  Sun, Weitong ^a   Zou, Weiwei ^a   Huang, Guihua ^a   Li, Aiguo ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Biodistribution; Liposome sizes; Pharmacokinetics; TFu loaded liposomes

Indexed keywords

FLUOROURACIL DERIVATIVE; LIPOSOME; N3 O TOLUYL FLUOROURACIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG RELEASE; DRUG SOLUTION; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PARTICLE SIZE; PARTITION COEFFICIENT; PRIORITY JOURNAL; SUSPENSION; THIN LAYER CHROMATOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; FLUOROURACIL; INFUSIONS, INTRAVENOUS; LIPOSOMES; MICE; PRODRUGS; TISSUE DISTRIBUTION;

EID: 46649085083     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860801927598     Document Type: Article

References (36)

1. Avgoustakis, K., Beletsi, A., Panagi, Z., Klepetsanis, P., Karydas, AG and Ithakissios, DS (2002) PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release, 79, pp. 123-135.
2. Beall, HD and Sloan, KB (2001) Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyl-5-FU prodrugs. Int J Pharm, 217, pp. 127-137.
3. Campbell, PI (1983) Toxicity of some charged lipids used in liposomes preparation. Cytobios, 37, pp. 21-26.
4. Cattel, L., Ceruti, M. and Dosio, F. (2003) From conventional to stealth liposomes: A new frontier in cancer chemotherapy. Tumori, 89, pp. 237-249.
5. Delie, F. (1998) Evaluation of nano- and microparticles uptake by the gastrointestinal tract. Adv Drug Deliv Rev, 34, pp. 221-233.
6. Desai, MP, Labhasetwar, V., Amidon, GL and Levy, RJ (1996) Gastrointestinal uptake of biodegradable microparticles: Effect of particle size. Pharm Res, 13, pp. 1838-1845.
7. Deshmukh, DS, Bear, WD and Brockerhoff, H. (1980) Can intact liposomes be absorbed in the gut?. Life Sci, 28, pp. 239-242.
8. Eldridge, JH, Hammond, CJ, Meulbroek, JA, Staas, JK, Gilley, RM and Tice, TR (1990) Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release, 11, pp. 205-214.
9. Elhissi, AM, O'Neill, MA, Roberts, SA and Taylor, KM (2006) A calorimetric study of dimyristoylphosphatidylcholine phase transitions and steroid-liposomes interactions for liposomes prepared by thin film and proliposomes methods. Int J Pharm, 320, pp. 124-130.
10. Fahr, A., Van Hoogevest, P., May, S., Bergstrand, N., S Leigh, ML and May, S. (2005) Transfer of lipophilic drugs between liposomal membranes and biological interfaces: Consequences for drug delivery. Eur J Pharm Sci, 26, pp. 251-265.
11. Florence, AT, Hillery, AM, Hussain, N. and Jani, PU (1995) Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J Control Release, 36, pp. 39-46.
12. Fraile, RJ, Baker, LH, Buroker, TR, Horwitz, J. and Vaitkevicius, VK (1980) Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res, 40, pp. 2223-2228.
13. Goyal, P., Goyal, K., Vijaya Kumar, SG, Singh, A., Katare, OP and Mishra, DN (2005) Liposomal drug delivery systems-clinical applications. Acta Pharm, 55, pp. 1-25.
14. Kaiser, N., Kimpfler, A., Massing, U., Burger, AM, Fiebig, HH, Brandl, M. and Schubert, R. (2003) 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: Entrapment and release properties. Int J Pharm, 256, pp. 123-131.
15. Kametani, T., Kigasawa, K., Hiiragi, M., Wakisaka, K., Haga, S., Nagamatsu, Y., Sugi, H., Fukawa, K., Irino, O., Yamamoto, T., Nishimura, N., Taguchi, A., Okada, T. and Nakayama, M. (1980) Studies on the Synthesis of Chemotherapeutics 10 Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives. J Med Chem, 23, pp. 1324-1329.
16. Leigh, M., van Hoogevest, P. and Tiemessen, H. (2001) Optimising the oral bioavailability of the poorly water-soluble drug cyclosporin A using membrane lipid technology. Drug Deliv Syst Sci, 1, pp. 73-77.
17. Li, Y. and Mitra, AK (1996) Effect of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption. Pharm Res, 13, pp. 76-79.
18. Lian, T. and Ho, RJ (2001) Trends and developments in liposome drug delivery systems. J Pharm Sci, 90, pp. 667-680.
19. Lidgate, DM, Felgner, PL, Fleitman, JS, Whatley, J. and Fu, RC (1988) In vitro and in vivo studies evaluating a liposomes system for drug solubilization. Pharm Res, 5, pp. 759-764.
20. Liu, D., Mori, A. and Huang, L. (1992) Role of liposomes size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposome. Biochim Biophys Acta, 1104, pp. 95-101.
21. Liu, L., Jin, P., Cheng, M., Zhang, G. and Zhang, FB (2006) FB5-Fluorouracil-loaded self-assembled pH-sensitive nanoparticles as novel drug carrier for treatment of malignant tumors. Chin J Chem Eng, 14, pp. 377-382.
22. Liversidge, GG and Cundy, KC (1995) Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125, pp. 91-97.
23. Manjunath, K. and Venkateswarlu, V. (2005) Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release, 107, pp. 215-228.
24. Mayer, LD, Bally, MB, Loughrey, H., Masin, D. and Cullis, PR (1990) Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res, 50, pp. 575-579.
25. Nagayasu, A., Uchiyama, K. and Kiwada, H. (1999) The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev, 40, pp. 75-87.
26. Pauletti, GM and Wunderli-Allenspach, H. (1994) Partition coefficients in vitro: Artificial membranes as a standardized distribution model. Eur J Pharm Sci, 1, pp. 273-282.
27. Peters, GJ, Lankelma, J., Kok, RM, Noordhuis, P., van Groeningen, CJ, van der Wilt, CL, Meyer, S. and Pinedo, HM (1993) Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol, 269, p. 276.
28. Plember van Balen, G, Caron, G., Ermondi, G., Pagliara, A., Grandi, T., Bouchard, G., Fruttero, R., Carrupt, PA and Testa, B. (2001) Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm Res, 18, pp. 694-701.
29. Portney, NG and Ozkan, M. (2005) Nano-oncology: Drug delivery, imaging, and sensing. Anal Bioanal Chem, 384, pp. 620-630.
30. Pupo, E., Padron, A., Santana, E., Sotolongo, J., Quintana, D., Duenas, S., Duarte, C., de la Rosa, MC and Hardy, E. (2005) Preparation of plasmid DNA-containing liposomes using a high-pressure homogenizationextrusion technique. J Control Release, 104, pp. 379-396.
31. Sun, WT, Huang, GH, Ye, JS and Zhang, N. (2006) Determination encapsulation efficiencies of liposomes and nanoliposomes by protamine aggregation method. Chin Pharm J, 41, pp. 43-47.
32. Van Balen, GP, Martinet, CM, Caron, G., Bouchard, G., Reist, M., Carrupt, PA, Fruttero, R., Gasco, A. and Testa, B. (2004) Liposome/water lipophilicity: Methods, information content, and pharmaceutical applications. Med Res Rev, 24, pp. 299-324.
33. Vasir, JK, Tambwekar, K. and Garg, S. (2003) Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm, 255, pp. 13-32.
34. Yang, YB, Tang, ZQ and Zhang, P. (2004) The pharmacokinetics of atofluding in cancer patients. Chin J New Drugs, 10, pp. 196-198.
35. Yu, HY and Liu, RF (1994) Hepatic uptake and tissue distribution of liposomes: Influence of vesicle size. Drug Dev Ind Pharm, 20, pp. 557-574.
36. Zhou, W., Ping, QN and Wang, LJ (2005) Influence of particle size on the tissue distribution of hydroxycamptothecin liposomes. J China Pharm Univ, 36, pp. 125-128.